HK1148530A1 - 2, 3-dihydrobenzo[1, 4] dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases 2c 23-[14]- 2- - Google Patents

2, 3-dihydrobenzo[1, 4] dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases 2c 23-[14]- 2-

Info

Publication number
HK1148530A1
HK1148530A1 HK11102788.9A HK11102788A HK1148530A1 HK 1148530 A1 HK1148530 A1 HK 1148530A1 HK 11102788 A HK11102788 A HK 11102788A HK 1148530 A1 HK1148530 A1 HK 1148530A1
Authority
HK
Hong Kong
Prior art keywords
peripheric
systeme
dihydrobenzo
dioxin
diseases
Prior art date
Application number
HK11102788.9A
Other languages
English (en)
Chinese (zh)
Inventor
David Dinbelle
Patrik Holm
Arto Karljalainen
Arto Tolvanen
Gerd Wohlfahrt
Petteri Rummakko
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39884455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1148530(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of HK1148530A1 publication Critical patent/HK1148530A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/101,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/141,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/161,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK11102788.9A 2007-07-20 2011-03-21 2, 3-dihydrobenzo[1, 4] dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases 2c 23-[14]- 2- HK1148530A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95098307P 2007-07-20 2007-07-20
PCT/FI2008/000090 WO2009013390A1 (en) 2007-07-20 2008-07-18 2, 3-dihydrobenzo[1, 4] dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases

Publications (1)

Publication Number Publication Date
HK1148530A1 true HK1148530A1 (en) 2011-09-09

Family

ID=39884455

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11102788.9A HK1148530A1 (en) 2007-07-20 2011-03-21 2, 3-dihydrobenzo[1, 4] dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases 2c 23-[14]- 2-

Country Status (32)

Country Link
US (3) US8492549B2 (xx)
EP (1) EP2176252B1 (xx)
JP (1) JP5460590B2 (xx)
KR (1) KR101535059B1 (xx)
CN (1) CN101842369B (xx)
AR (1) AR069271A1 (xx)
AU (1) AU2008278924B2 (xx)
BR (1) BRPI0814529B8 (xx)
CA (1) CA2693804C (xx)
CL (1) CL2008002114A1 (xx)
CO (1) CO6331473A2 (xx)
CY (1) CY1115789T1 (xx)
DK (1) DK2176252T3 (xx)
EA (1) EA017554B1 (xx)
ES (1) ES2502215T3 (xx)
GE (1) GEP20125538B (xx)
HK (1) HK1148530A1 (xx)
HR (1) HRP20141156T1 (xx)
IL (1) IL202964A (xx)
MA (1) MA31521B1 (xx)
MY (1) MY153872A (xx)
NZ (1) NZ582432A (xx)
PE (1) PE20090890A1 (xx)
PL (1) PL2176252T3 (xx)
PT (1) PT2176252E (xx)
RS (1) RS53571B1 (xx)
SI (1) SI2176252T1 (xx)
TN (1) TN2010000029A1 (xx)
TW (1) TWI457122B (xx)
UA (1) UA100695C2 (xx)
WO (1) WO2009013390A1 (xx)
ZA (1) ZA201000314B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3-二氫苯並[1,4]戴奧辛-2-基甲基衍生物
DK2271638T3 (da) 2008-04-29 2011-11-28 Nsab Af Neurosearch Sweden Ab Modulatorer af dopaminneurotransmission
JP2011519839A (ja) * 2008-04-29 2011-07-14 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ ドーパミン神経伝達のモジュレーター
MX2010011724A (es) * 2008-04-29 2010-11-30 Nsab Af Neurosearch Sweden Ab Moduladores de neurotransmision de dopamina.
TW201024282A (en) * 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
US8822679B2 (en) * 2011-06-24 2014-09-02 California Institute Of Technology Quaternary heteroatom containing compounds
US20130267699A1 (en) 2011-06-24 2013-10-10 California Institute Of Technology Quaternary heteroatom containing compounds
US9518034B2 (en) 2013-10-14 2016-12-13 California Institute Of Technology Synthesis of chiral enaminones, their derivatives, and bioactivity studies thereof
US10421696B2 (en) 2014-12-18 2019-09-24 California Institute Of Technology Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation
CN105985389B (zh) * 2015-03-06 2019-03-19 北京大学 苯乙醇苷类似物及其合成方法和应用
CA2981041C (en) 2015-03-27 2023-09-05 California Institute Of Technology Asymmetric catalytic decarboxylative alkyl alkylation using low catalyst concentrations and a robust precatalyst
TWI704145B (zh) 2015-06-05 2020-09-11 芬蘭商奧利安公司 新醫藥化合物
EP3426391A4 (en) 2016-03-11 2019-08-28 California Institute of Technology COMPOSITIONS AND METHODS FOR ACYLATING LACTAMEN
JP2019519582A (ja) 2016-06-29 2019-07-11 オリオン コーポレーション ベンゾジオキサン誘導体およびその医薬用途
WO2018169818A1 (en) * 2017-03-12 2018-09-20 Xiaodong Wang Polycyclic amines as opioid receptor modulators
EP3480190B1 (en) 2017-11-01 2023-01-04 California Institute of Technology Methods for enantioselective allylic alkylation of esters, lactones, and lactams with unactivated allylic alcohols
GB201801130D0 (en) * 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
US11214568B2 (en) 2018-10-18 2022-01-04 California Institute Of Technology Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same
WO2023131640A1 (en) 2022-01-07 2023-07-13 Bayer Aktiengesellschaft α2-ADRENOCEPTOR SUBTYPE C ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA
KR20230114646A (ko) * 2022-01-25 2023-08-01 재단법인 한국파스퇴르연구소 벤조다이옥세인 유도체 화합물 및 이의 의약 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2056046A (en) 1933-05-19 1936-09-29 Rhone Poulenc Sa Manufacture of bases derived from benz-dioxane
US3647790A (en) 1969-04-08 1972-03-07 American Home Prod Ouinoxalinyl-oxazolidines and -oxazines
GB1411531A (en) 1972-10-24 1975-10-29 Lafon Labor Amino derivatives of 1,4-benzodioxan
JPS5163193A (ja) * 1974-11-26 1976-06-01 Yoshitomi Pharmaceutical Tetorahidoropirazoropirijinkagobutsuno seizoho
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
US4329348A (en) * 1979-02-26 1982-05-11 Ciba-Geigy Corporation N-Oxacyclic-alkylpiperidines as psychostimulants
HU181575B (en) 1980-10-03 1983-10-28 Richter Gedeon Vegyeszet Process for preparing 3-chloro-propyl-malonic acid ester and cyano-acetic acid ester derivatives
FR2525600A1 (fr) * 1982-04-21 1983-10-28 Bouchara Emile Nouvelles carboxamidoguanidines, leur procede d'obtention et les compositions pharmaceutiques en renfermant
GB2167408B (en) 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
DD250930A1 (de) 1986-06-08 1987-10-28 Isis Chemie Zwickau Veb Verfahren zur herstellung neuer tetrahydroisochinolinderivate
US4957928A (en) * 1986-06-26 1990-09-18 Ciba-Geigy Corporation Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
EP0429535A1 (en) 1988-08-16 1991-06-05 E.I. Du Pont De Nemours And Company Fungicidal benzodioxane amine derivatives
EP0573581A4 (en) 1991-02-26 1994-06-29 Arc 1 Inc Compositions and methods of treatment of sympathetically maintained pain
GB9318431D0 (en) * 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents
GB9514380D0 (en) 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
FR2744451B1 (fr) 1996-02-01 1998-04-24 Pf Medicament Nouvelles imidazolidinones, pyrimidinones, et 1,3-diazepin-2 -ones, leur preparation et leurs applications en therapeutique
EP0983239A1 (en) 1997-05-06 2000-03-08 Novo Nordisk A/S Novel heterocyclic compounds
US5902807A (en) 1997-05-12 1999-05-11 Antti Haapalinna Method for the treatment of mental illness in mammals and a composition therefor
NZ504667A (en) 1997-12-04 2003-03-28 Allergan Sales Inc Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors
FI20000480A0 (fi) 2000-03-01 2000-03-01 Orion Yhtymae Oyj Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
AU9087301A (en) * 2000-09-11 2002-03-26 Sepracor Inc Ligands for monoamine receptors and transporters, and methods of use thereof
IL164203A0 (en) 2002-04-03 2005-12-18 Orion Corp Polycyclic compounds as potent alpah2-adrenoceptorantagonists
WO2004067513A1 (en) 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3-二氫苯並[1,4]戴奧辛-2-基甲基衍生物
JP5163193B2 (ja) 2008-03-13 2013-03-13 セイコーエプソン株式会社 プリンタシステム及びプリンタシステムにおける制御方法

Also Published As

Publication number Publication date
US8492549B2 (en) 2013-07-23
PE20090890A1 (es) 2009-07-08
US20130281486A1 (en) 2013-10-24
TN2010000029A1 (en) 2011-09-26
KR20100044220A (ko) 2010-04-29
ZA201000314B (en) 2010-10-27
AU2008278924B2 (en) 2013-09-26
US20120035210A9 (en) 2012-02-09
CN101842369B (zh) 2014-01-22
EP2176252A1 (en) 2010-04-21
BRPI0814529B8 (pt) 2021-05-25
UA100695C2 (ru) 2013-01-25
WO2009013390A1 (en) 2009-01-29
DK2176252T3 (en) 2014-12-08
TW200908961A (en) 2009-03-01
JP5460590B2 (ja) 2014-04-02
CN101842369A (zh) 2010-09-22
US8697723B2 (en) 2014-04-15
JP2010534197A (ja) 2010-11-04
PT2176252E (pt) 2014-12-03
ES2502215T3 (es) 2014-10-03
BRPI0814529A2 (pt) 2015-01-27
SI2176252T1 (sl) 2014-12-31
MA31521B1 (fr) 2010-07-01
AU2008278924A1 (en) 2009-01-29
CY1115789T1 (el) 2017-01-25
RS53571B1 (en) 2015-02-27
PL2176252T3 (pl) 2015-04-30
MY153872A (en) 2015-03-31
TWI457122B (zh) 2014-10-21
BRPI0814529B1 (pt) 2019-09-17
EA017554B1 (ru) 2013-01-30
KR101535059B1 (ko) 2015-07-24
EP2176252B1 (en) 2014-09-03
NZ582432A (en) 2012-03-30
CL2008002114A1 (es) 2009-04-03
US8809536B2 (en) 2014-08-19
AR069271A1 (es) 2010-01-13
EA201070169A1 (ru) 2010-06-30
US20100216836A1 (en) 2010-08-26
IL202964A (en) 2013-12-31
HRP20141156T1 (hr) 2015-01-16
GEP20125538B (en) 2012-05-25
CO6331473A2 (es) 2011-10-20
CA2693804C (en) 2015-11-24
US20140179926A1 (en) 2014-06-26
CA2693804A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
HK1148530A1 (en) 2, 3-dihydrobenzo[1, 4] dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases 2c 23-[14]- 2-
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
HK1220631A1 (zh) 用於遞送治療劑的陰離子核心組合物以及製備和使用所述組合物的方法
MX2020012868A (es) Metodos y composiciones para trastornos del sue?o y otros trastornos.
IL216238A0 (en) 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof, and therapeutic use thereof
ZA200907245B (en) Phthalazinone derivatives and their use as medicament to treat cancer
IL205608A (en) History of s-triazole-1-ram-benzamide and their use in the preparation of pain medication
EP2401263A4 (en) SUBSTITUTED AZOL DERIVATIVES, PHARMACEUTICAL COMPOSITION WITH THE DERIVATIVES AND METHOD FOR THE TREATMENT OF MORBUS PARKINSON THEREWITH
EP2217238A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA
SI2328417T1 (sl) Spojine, sestavki in postopki za zdravljenje beta amiloidnih bolezni in sinukleinopatije
IL207356A0 (en) 5, 6 - bisaryl-2- pyridine - carboxamide derivatives, preparation thereof and therapeutic application thereof as antagonists for urotensine ii receptors
EP2148667A4 (en) USE OF CYCLOHEXANHEXOL DERIVATIVES IN THE TREATMENT OF EYE DISEASES
IL216228A0 (en) 5-membered heterocyclic compound cyclopenta[c] pyrrolylakyl carbamate derivaties, preparation thereof, and therapeutic use thereof
IL217300A0 (en) Pyrazole derivatives' prepartion thereof, and therapeutic use thereof
EP2207555A4 (en) NOVEL COMPOUNDS FOR THE TREATMENT OR MITIGATION OF OEDEMES, AND METHODS OF USE THEREOF
IL215103A0 (en) N-[(6-AZA-bicyclo[3.2.1]OCT-5-YL]-ARYL-METHYL]-HETEROBENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE OF SAME
HK1158632A1 (en) Derivatives of 2-oxo-alkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same 2--1--2-
HK1126200A1 (en) Isoquinoline et benzo[h]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine h3 receptor
ZA201000745B (en) Tricyclic n-heteroaryl-carboxamide derivatives,preparation thereof and therapeutic use of same
IL213606A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of inflamatory skin diseases
ZA201100251B (en) Substituted 1-benzyl-cinnolin-4(1h)-one derivatives,preparation thereof,and therapeutic use thereof
IL202474A0 (en) 1-benzylpyrazole derivatives, preparation thereof and therapeutic use thereof
ZA201000582B (en) 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives,preparation and therapeutic use thereof
GB0716834D0 (en) New formulation for treatment of skin disorders
IL178853A0 (en) Tar composition for the treatment of skin diseases